Growth Hormone-Releasing Peptide-2
Also known as: GHRP-2, Growth Hormone Releasing Peptide-2, KP-102, Pralmorelin, Pralmorelin hydrochloride
4 notable studies · 3 references
TLDR
GHRP-2 is a synthetic ghrelin-receptor agonist with established human growth-hormone-stimulating activity and a history of use in endocrine research and diagnostic testing, but evidence for popular body-composition, recovery, and anti-aging applications remains inadequate and long-term safety is not established.
Research Supports
- Studied for stimulating endogenous growth hormone secretion via the ghrelin/GHS receptor
- Investigated as a provocative diagnostic test for pituitary growth hormone reserve
- Studied for effects on ACTH and cortisol via hypothalamic-pituitary-adrenal signaling
- Investigated for effects on appetite and energy regulation through ghrelin-receptor activity
- Used as a research tool to help characterize ghrelin-receptor pharmacology before ghrelin was identified
Observations Reported in Research
- Combined GHRH + GHRP-2 stimulation can produce a greater GH response than either pathway alone
- Retrospective study of 69 patients: cortisol responses during GHRP-2 stimulation helped distinguish hypothalamic secondary adrenal insufficiency (2026)
- A peak cortisol below 12 micrograms/dL during GHRP-2 stimulation was specific for hypothalamic secondary adrenal insufficiency in a patient subset (2026 study)
- FDA noted reported adverse events including increased insulin requirements, infections, and pancreatitis among people who received GHRP-2, though causality was not established
These are brief summaries of what the referenced research examined or reported — not conclusions about safety or effectiveness, and not medical advice. See Notable Studies and Sources & References below for the full context and citations.
At a Glance
Classification: Synthetic hexapeptide; growth hormone secretagogue; ghrelin/growth hormone secretagogue receptor agonist
GHRP-2 is a synthetic six-amino-acid peptide that stimulates growth hormone secretion primarily through the growth hormone secretagogue receptor, GHS-R1a, now commonly called the ghrelin receptor. It belongs to an older generation of synthetic growth hormone secretagogues that helped researchers characterize the signaling system later associated with the endogenous hormone ghrelin. Unlike GHRH analogues such as tesamorelin and CJC-1295, GHRP-2 does not primarily activate the GHRH receptor. It instead acts through the ghrelin/GHS receptor and can interact synergistically with endogenous GHRH signaling. GHRP-2 has been administered to humans in endocrine research and has been investigated as a diagnostic stimulus for pituitary function. However, it is not FDA-approved in the United States, and evidence supporting popular claims involving muscle growth, fat loss, recovery, or anti-aging is inadequate. FDA currently identifies injectable and nasal compounded GHRP-2 as potentially presenting significant safety risks, including concerns involving immunogenicity, aggregation, peptide impurities, glucose regulation, and serious adverse events for which causality has not necessarily been established.
What Is Growth Hormone-Releasing Peptide-2?
GHRP-2 is a synthetic hexapeptide originally developed as part of the growth hormone-releasing peptide family. Its sequence is commonly represented as: D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH₂ GHRP-2 was developed before ghrelin itself was discovered. Researchers initially knew that synthetic GHRPs stimulated growth hormone through a mechanism distinct from GHRH. The receptor responsible—the growth hormone secretagogue receptor—was identified before its natural ligand. The discovery of ghrelin in 1999 subsequently revealed the endogenous signaling system that these synthetic compounds had been activating. This makes GHRP-2 historically important: compounds like it helped researchers uncover an entirely new neuroendocrine pathway controlling growth hormone secretion, appetite, metabolism, and gastrointestinal physiology.
What Are Researchers Studying?
Growth hormone secretion
GHRP-2 is a potent stimulator of endogenous growth hormone release. Human studies have repeatedly demonstrated substantial GH responses after administration. Because it works through a different receptor system from GHRH, researchers have also investigated interactions between the two pathways. Combined stimulation can produce a GH response greater than either pathway alone, demonstrating functional cooperation between GHRH and ghrelin/GHS signaling.
Pituitary function and growth hormone deficiency
GHRP-2 has been investigated as a provocative endocrine test for evaluating pituitary growth hormone reserve. Rather than treating growth hormone deficiency directly, researchers administer a secretagogue and measure the resulting GH response. GHRP-2 testing has been particularly studied as an alternative when the traditional insulin tolerance test is undesirable or contraindicated. Research continues to examine diagnostic thresholds and how GHRP-2 responses differ among pituitary and hypothalamic disorders.
Hypothalamic-pituitary-adrenal signaling
GHRP-2 does not exclusively affect growth hormone. Research has demonstrated effects on ACTH and cortisol, reflecting interactions between ghrelin/GHS signaling and the hypothalamic-pituitary-adrenal axis. This is one of the important distinctions between GHRP-2 and the more GH-selective secretagogue ipamorelin. Consequently, cortisol responses to GHRP-2 have themselves been investigated as potential indicators of hypothalamic-pituitary function. Recent 2026 clinical research continues to examine GHRP-2 stimulation in differentiating forms of secondary adrenal insufficiency.
Appetite and energy regulation
The ghrelin receptor plays an important role in appetite and energy balance. Because GHRP-2 activates this receptor system, researchers have investigated its effects on food intake and appetite in humans and experimental models. This distinguishes GHRP-2 mechanistically from GHRH analogues. Growth-hormone secretion is only one component of the broader biology of the ghrelin receptor.
Ghrelin-receptor pharmacology
GHRP-2 has served as an important experimental tool for understanding the growth hormone secretagogue receptor. Studies involving GHRP-2 and related compounds helped researchers characterize a receptor pathway before the endogenous ligand ghrelin had even been identified. Following the discovery of ghrelin, GHRP-2 became useful for comparing synthetic secretagogues with the natural hormone.
Diagnostic testing
GHRP-2 has been investigated extensively as a diagnostic stimulus for assessing pituitary and hypothalamic function. Clinical researchers have compared GHRP-2 stimulation with insulin tolerance testing and other endocrine provocative tests. This is an important distinction from many research peptides: a substantial portion of the human GHRP-2 literature involves diagnostic endocrinology, not attempts to produce changes in body composition or athletic performance.
How Does It Work?
GHRP-2 primarily activates GHS-R1a, the growth hormone secretagogue/ghrelin receptor. Activation of this receptor within the hypothalamus and pituitary promotes growth hormone secretion. The GH response involves both direct pituitary signaling and hypothalamic regulation. GHRP-2 can also interact with the endogenous GHRH system. This produces an important endocrine phenomenon: stimulation of the ghrelin receptor and GHRH receptor together can produce greater GH release than stimulation of either pathway independently. That is why: Tesamorelin / CJC-1295 → GHRH receptor while GHRP-2 / GHRP-6 / Ipamorelin → GHS-R1a / ghrelin receptor The systems interact, but the compounds do not act through the same primary receptor. GHS-R1a signaling also influences appetite, gastrointestinal function, glucose regulation, and hypothalamic-pituitary-adrenal signaling. Consequently, GHRP-2's effects are not restricted to growth hormone.
What Does the Research Show?
Human research
GHRP-2 has a meaningful human experimental literature. Human studies have demonstrated that GHRP-2 can provoke substantial GH secretion in healthy individuals and in patients undergoing endocrine evaluation. Researchers have subsequently investigated GHRP-2 stimulation as a diagnostic test for: • Adult growth hormone deficiency • Pediatric growth hormone deficiency • Hypopituitarism • Hypothalamic dysfunction • Secondary adrenal insufficiency The continued appearance of GHRP-2 stimulation testing in contemporary endocrine research demonstrates that its physiological effects in humans are well established. For example, a 2026 clinical study retrospectively evaluated 69 patients who had undergone endocrine testing and found that cortisol responses during GHRP-2 stimulation could provide additional information when differentiating hypothalamic secondary adrenal insufficiency. However, evidence that GHRP-2 can stimulate GH should not be confused with evidence that long-term GHRP-2 administration improves muscle mass, fat loss, recovery, longevity, or athletic performance. Those are different clinical questions.
Animal research
Animal research has been central to understanding GHRP-2's neuroendocrine pharmacology. Experiments have investigated: • GH secretion • Hypothalamic signaling • Pituitary responses • Appetite and food intake • ACTH and cortisol regulation • Glucose metabolism • Interaction with GHRH and somatostatin • Ghrelin-receptor signaling These experiments helped establish that synthetic GHRPs operate through a receptor system distinct from GHRH. Later identification of ghrelin provided the endogenous physiological context for many of those observations.
In-vitro research
Cellular and receptor experiments have established GHRP-2 as an agonist of GHS-R1a. Laboratory studies have examined receptor binding, intracellular calcium signaling, pituitary GH secretion, receptor desensitization, and interactions with other endocrine signaling pathways. These experiments provide strong evidence for GHRP-2's receptor pharmacology. They do not establish long-term clinical benefit.
Notable Studies
Growth Hormone-Releasing Peptide-2: Clinical and Experimental Characterization of Growth Hormone Secretagogue Activity
humanEarly human studies investigated whether GHRP-2 could stimulate growth hormone secretion independently of the classical GHRH pathway. Researchers demonstrated robust GH responses and established GHRP-2 as a potent synthetic growth hormone secretagogue. These experiments helped establish the existence of a distinct regulatory pathway controlling GH release.
Limitations: The studies primarily measured acute endocrine responses. Demonstrating increased circulating GH does not establish long-term improvements in body composition, physical performance, recovery, or health outcomes.
GHRP-2 Stimulation Testing for the Diagnosis of Growth Hormone Deficiency
humanResearchers evaluated whether the GH response following GHRP-2 administration could identify impaired pituitary growth hormone reserve. The accumulated literature established GHRP-2 stimulation as a useful research and diagnostic approach and led to its use in endocrine testing in Japan.
Limitations: Diagnostic accuracy depends on the population, assay, diagnostic threshold, and underlying pituitary disorder. A diagnostic use does not establish therapeutic benefit from repeated GHRP-2 exposure.
Differentiating Hypothalamic From Pituitary Adrenal Insufficiency: Underlying Causes and Diagnostic Utility of the Corticotropin-Releasing Hormone and Growth Hormone-Releasing Peptide-2 Stimulation Tests
humanResearchers analyzed 69 patients who underwent endocrine provocative testing. Among patients with secondary adrenal insufficiency, GHRP-2-associated cortisol responses provided additional information useful for identifying hypothalamic dysfunction. A peak cortisol below 12 μg/dL during GHRP-2 stimulation was specific for hypothalamic secondary adrenal insufficiency among a subset of patients with otherwise normal cortisol responses during CRH testing.
Limitations: This was a retrospective diagnostic study rather than an interventional treatment trial. The findings concern interpretation of endocrine testing and do not establish therapeutic benefits from GHRP-2.
View publication →FDA Evaluation of Potential Safety Risks Associated With Compounded GHRP-2
animalFDA evaluated available information concerning compounded GHRP-2 intended for injectable and nasal administration. The agency identified potential immunogenicity concerns involving peptide aggregation and impurities. It also noted that GHRP-2 contains an unnatural amino acid, adding complexity to characterization. FDA reports awareness of serious adverse events among people who received GHRP-2, including increased insulin requirements, infections, pancreatitis, and deaths among critically ill study participants. Importantly, FDA states that causality has not been established for these reports.
Limitations: This is a regulatory safety assessment rather than a controlled efficacy trial. Reported adverse events do not by themselves establish that GHRP-2 caused the events.
View publication →What We Still Don't Know
Important unanswered questions include: • Long-term safety of repeated GHRP-2 exposure • Long-term effects on glucose metabolism and insulin sensitivity • Clinical significance of repeated ACTH/cortisol stimulation • Whether chronic GHRP-2 administration meaningfully improves body composition • Whether it increases muscle strength or physical performance • Whether it improves recovery from injury or exercise • Long-term cardiovascular effects • Effects of sustained GH/IGF-1 elevation • Immunogenicity with repeated exposure • Consequences of peptide aggregation and impurities • Whether different formulations have equivalent pharmacology • Whether common nonclinical uses produce benefits that outweigh potential endocrine effects FDA currently places GHRP-2 intended for injectable and nasal routes in Category 2, meaning the agency has identified potential significant safety risks while evaluating the substance for compounding.
Related Compounds
Recent publications
Latest titles from PubMed, not reviewed by Aminodex. Not an endorsement. See all on PubMed ↗
Take the Growth Hormone-Releasing Peptide-2 research with you.
Get the Aminodex Growth Hormone-Releasing Peptide-2 Brief—a concise summary of the research, notable studies, evidence types, limitations, and references.
One-time email. We do not add you to any mailing list.
Sources & References
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the First Selective Growth Hormone Secretagogue. European Journal of Endocrinology. 1998;139(5):552–561. Comparative pharmacology includes GHRP-2.
- Differentiating Hypothalamic From Pituitary Adrenal Insufficiency: Underlying Causes and Diagnostic Utility of the Corticotropin-Releasing Hormone and Growth Hormone-Releasing Peptide-2 Stimulation Tests. 2026.
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks: Growth Hormone Releasing Peptide-2.
Supplier Listings
A directory of relevant research suppliers for this compound is not yet available.